Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What key factors are powering the surge in the chronic plaque psoriasis market right now?

Recent years have witnessed a robust growth in the size of the chronic plaque psoriasis market. The market, which is predicted to increase from $20.79 billion in 2024 to $22.32 billion in 2025, is expected to experience a compound annual growth rate (CAGR) of 7.3%. Key factors fueling this growth during the historical period include a surge in psoriasis cases, growing co-morbidities prevalence, encouraging reimbursement policies, a rise in alcohol and tobacco usage, along with the advent of telemedicine.

How fast Is the chronic plaque psoriasis market expected to grow, and what’s its future value?

The market for chronic plaque psoriasis is anticipated to experience significant expansion over the coming years. With a predicted compound annual growth rate (CAGR) of 7.1%, it’s estimated to reach a market size of $29.33 billion by 2029. Several factors contribute to this growth, including a global rise in the prevalence of cpp, an increase in autoimmune diseases, expanding healthcare budgets, an aging population, and a growing demand for efficacious treatments. Key trends to watch for in this forecast period are developments in biologic treatments, the inception of oral small molecule inhibitors, the integration of digital health, personalized medicine, and the introduction of biosimilars.

Get your chronic plaque psoriasis market report here!

https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

What are the leading drivers of growth in the chronic plaque psoriasis market?

An uptick in immune system dysfunction cases is anticipated to spur the chronic plaque psoriasis market’s advancement. Immune system dysfunction is a state in which the immune system’s operation is compromised, leading to heightened risk of infections, autoimmune diseases, and cancer. This increase is attributed to elements such as hereditary propensity, environmental factors, poor nutrition, chronic stress, and a surge in autoimmune diseases and infections, including HIV. Treatment for chronic plaque psoriasis is necessary to balance immune system dysfunction, which erroneously triggers an excessive production of skin cells, causing inflammation and plaque creation. As an illustration, in December 2022, the National Psoriasis Foundation, a nonprofit organization based in the US, documented that psoriasis affects more than 8 million Americans. Worldwide, this condition affects 125 million individuals, representing 2 to 3% of the total global population. Consequently, the escalating instances of immune system dysfunction are instrumental in the growth surge of the chronic plaque psoriasis market.

What are the key segments defining the chronic plaque psoriasis market?

The chronic plaque psoriasis market covered in this report is segmented –

1) By Drug Class: Biologics, Small Molecule Drugs

2) By Route Of Administration: Injectable, Oral, Topical

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Subsegments:

1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22), T-Cell Inhibitors, Others

2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors, Janus Kinase (JAK) Inhibitors, Retinoids, Others

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp

Who are the key players steering the development of the chronic plaque psoriasis market?

Major companies operating in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Biogen Inc., UCB S.A., Dr. Reddy’s Laboratories, Innovent Biologics Inc., Dong-A ST Co. Ltd., Alumis GmbH Co KG, Zai Lab Limited, GC Cell Corporation, Affibody AB, Nimbus Therapeutics, Bio-Thera Solutions, Can-Fite Biopharma, Celgene Corporation, Kadmon Pharmaceuticals, Aldeyra Therapeutics Inc., Arcutis Biotherapeutics

What are the key trends shaping the future of the chronic plaque psoriasis market?

Major companies operating in the chronic plaque psoriasis market are focusing on developing innovative treatments, such as IL-17A and IL-17F inhibitors, to gain advancement in the treatment of chronic plaque psoriasis. IL-17A and IL-17F inhibitors are targeted biologic therapies that block interleukin-17A and interleukin-17F, pro-inflammatory cytokines involved in the immune response, to reduce inflammation in autoimmune diseases like chronic plaque psoriasis. For instance, in October 2023, UCB S.A., a Belgium-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved BIMZELX (bimekizumab-bkzx) for adults with moderate to severe plaque psoriasis who are eligible for systemic therapy or phototherapy. Bimekizumab is the first approved medication for psoriasis specifically designed to target and inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines involved in inflammatory processes. Its approval was based on evidence from three Phase 3 multicenter trials—BE READY, BE VIVID, and BE SURE—which collectively assessed its safety and efficacy in 1,480 patients with moderate to severe plaque psoriasis.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20726

Which regions are most influential in expanding the chronic plaque psoriasis market?

North America was the largest region in the chronic plaque psoriasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Psoriasis Global Market Report 2025

https://thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

Autoimmune Disease Diagnosis Global Market Report 2025

https://thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Global G-CSF (Granulocyte Colony Stimulating Factors) Opportunities And Strategies Global Global Market Report 2025

https://thebusinessresearchcompany.com/report/granulocyte-colony-stimulating-factors-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: